Nils Brünner spends much of his time researching Internal medicine, Cancer, Pathology, Breast cancer and Endocrinology. Nils Brünner has included themes like Gastroenterology and Oncology in his Internal medicine study. The study incorporates disciplines such as Hematology, Immunology and Enzyme inhibitor in addition to Cancer.
The concepts of his Pathology study are interwoven with issues in Cancer cell, Prognostic variable and Survival analysis. His study in Breast cancer is interdisciplinary in nature, drawing from both Malignancy, Metastasis, Chemotherapy and Cancer biomarkers. His Endocrinology research incorporates elements of Receptor, Progesterone receptor, Estrogen receptor and Cell growth.
Nils Brünner focuses on Internal medicine, Cancer, Oncology, Breast cancer and Colorectal cancer. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Pathology. His study looks at the relationship between Endocrinology and fields such as Estrogen receptor, as well as how they intersect with chemical problems.
His studies in Cancer integrate themes in fields like Molecular biology, Cancer research and Blood plasma. His research integrates issues of Matrix metalloproteinase, Primary tumor, Disease and Hazard ratio in his study of Oncology. His Colorectal cancer study incorporates themes from Stage, Carcinoembryonic antigen and Bioinformatics.
Nils Brünner mainly focuses on Internal medicine, Colorectal cancer, Cancer, Oncology and Cancer research. His research links Gastroenterology with Internal medicine. His Colorectal cancer research includes elements of Prospective cohort study, Phases of clinical research and Bioinformatics.
His Cancer research is multidisciplinary, incorporating perspectives in Drug resistance and Pathology. In his research, Cetuximab is intimately related to KRAS, which falls under the overarching field of Oncology. His Cancer research study also includes
His primary areas of investigation include Cancer research, Cancer, Colorectal cancer, Breast cancer and Internal medicine. His work carried out in the field of Cancer research brings together such families of science as Cell, Copy-number variation, Pathology, Gene and Immunofluorescence. His Cancer research is multidisciplinary, incorporating elements of Immunohistochemistry, Protein kinase B, PI3K/AKT/mTOR pathway and CD44.
His work deals with themes such as Prospective cohort study, Bioinformatics and Confidence interval, which intersect with Colorectal cancer. His research integrates issues of Mutation, Epithelial–mesenchymal transition, microRNA and Docetaxel in his study of Breast cancer. Nils Brünner interconnects Gastroenterology, Surgery, Oncology and Genetic marker in the investigation of issues within Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Khalid Bajou;Agnès Noël;R. D. Gerard;Véronique Masson.
Nature Medicine (1998)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)
The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients
John A. Foekens;Harry A. Peters;Maxime P. Look;Henk Portengen.
Cancer Research (2000)
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Jan Grøndahl-Hansen;Ib Jarle Christensen;Christian Rosenquist;Nils Brünner.
Cancer Research (1993)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon;Michael J. Duffy;Ulf Håkan Stenman;Hans Lilja.
Clinical Chemistry (2008)
Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer
Jun Yu;Qiang Feng;Sunny Hei Wong;Dongya Zhang.
Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue
Helle Pedersen;Nils Brünner;Dorthe Francis;Kell Østerlind.
Cancer Research (1994)
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies
Khalid Bajou;Véronique Masson;Robert D. Gerard;Petra M. Schmitt.
Journal of Cell Biology (2001)
The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion
K. Danø;N. Behrendt;N. Brunner;V. Ellis.
Fibrinolysis and Proteolysis (1994)
Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis
Ross W. Stephens;Hans Jørgen Nielsen;Ib J. Christensen;Ole Thorlacius-Ussing.
Journal of the National Cancer Institute (1999)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: